Centre for Chronic Disease (CCD), College of Health & Biomedicine, Victoria University, Melbourne, Victoria, Australia.
1st Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia.
Biomed Pharmacother. 2017 Sep;93:370-375. doi: 10.1016/j.biopha.2017.06.036. Epub 2017 Jun 24.
Nitric oxide synthases (NOS) are a family of isoforms responsible for the synthesis of the potent dilator nitric oxide (NO). Expression of inducible NOS (iNOS) occurs in conditions of inflammation, and produces large amounts of NO. In pathological conditions iNOS is regarded as a harmful enzyme and is proposed to be a major contributor to diseases of the cardiovascular system such as atherosclerosis. In this review, we address the notion that iNOS is a detrimental enzyme in disease and discuss its potentially beneficial roles. Additionally, we describe other molecules associated with iNOS in diseases such as atherosclerosis, and current research on therapeutic inhibitors tested to reduced pathology associated with cardiovascular diseases (CVD).
一氧化氮合酶（NOS）是一组同工酶，负责合成强效扩张剂一氧化氮（NO）。诱导型一氧化氮合酶（iNOS）的表达发生在炎症条件下，并产生大量的 NO。在病理条件下，iNOS 被认为是一种有害的酶，被认为是心血管系统疾病如动脉粥样硬化的主要致病因素。在这篇综述中，我们讨论了 iNOS 在疾病中是一种有害酶的观点，并探讨了其潜在的有益作用。此外，我们还描述了与动脉粥样硬化等疾病相关的 iNOS 相关的其他分子，以及目前针对心血管疾病（CVD）相关病理的治疗性抑制剂的研究。
